fda green list import alert 66-80 glp-1 Food and Drug Administration Issues API FDA Import Alert: How to

Ensure the medication is always kept out of reach of children and pets

Patients initiating GLP-1 RA treatment (semaglutide, liraglutide, tirzepatide) were propensity scorematched (1:1) with RA controls not receiving GLP-1 RA therapy, balancing demographics, BMI categories, cardiovascular comorbidities, immunosuppressive therapies, and cardiometabolic medications

Dose escalation to $249-$299/mo at maintenance doses for injectable

In WT C57BL/6 male mice, systemic inhibition of DPP-4 activity with sitagliptin reduced TG excursion following oral olive oil gavage during a lipid tolerance test (LTT) (Figure 1C)

You stepped on the scale this morning and it said what you wanted it to say

Those with significant comorbidities, prior CSF diversion procedures, those currently using GLP-1 receptor agonists or dipeptidyl-peptidase 4 (DPP-4) inhibitors or taking drugs that were thought to reduce ICP were excluded